close

Pneumonia prevention

Pneumonia prevention

AstraZeneca surrenders rights to pneumonia prevention drugs for $ 11 million upfront, but keeps an eye on the game

AstraZeneca offloads pneumonia prevention drug to Aridis Pharmaceuticals through worldwide license agreement, which will net Big Pharma $ 11 million in cash and an additional $ 115 million down the line.

Usually these deals go the other way, with a large company taking over the rights to a smaller biotech candidate, but in this case the UK drugmaker is the one passing on an asset.

The monoclonal antibody candidate, called suvratoxumab, is ready for phase 3 testing after pre-mid-term data revealed that treatment resulted in a 47% reduction in pneumonia in patients under 65 who were on ventilators, Aridis said in a press release. Patients have also seen a reduction in the number of days needed in the ICU or hospital.

Data published in The Lancet in April, however, suggests that the the trial failed to reduce the incidence of pneumonia caused by Staphylococcus aureus infection, which is one of the main causes of ventilation-associated pneumonia. The analysis included the entire trial population of 767 patients. Aridis focused on a subset of 196 patients under the age of 65 upon discharge.

RELATED: JPM: Aridis CEO Truong Explains Why Pandemic Has Failed To Boost Antibiotic R&D And What Needs To Change

AstraZeneca will remain involved in suvratoxumab, as the new agreement gives the company a stake in Aridis and allows the first negotiations on future licenses. The upfront payment will add an additional $ 115 million for AstraZeneca if certain development and sales milestones are met.

Aridis plans to launch a phase 3 study in the fourth quarter. Biotechnology received 25 million euros for the study of the Initiative for Innovative Medicines of the European Commission.

“We are delighted to have been selected as an AstraZeneca licensee,” said Aridis CEO Vu Truong, Ph.D. “The strong data from the Phase 2 trial gives us an advantage to define the patient population, the primary endpoint and the design of the phase 3 clinical study to support a clear path to the phase 3 confirmatory trial. ”

Aridis, which focuses on the development of anti-infective treatments that can be used in combination with antibiotics, believes that suvratoxumab may address an unmet medical need in a high-risk population.

The drug looks a bit like what we see with COVID vaccines and mAbs: With pneumonia there are vaccines, such as those from Pfizer and Merck, for many different strains of bacterial pneumonia, but AZ also increases the arsenal with this antibody to help reduce the risk of the disease when it has already struck.

“Suvratoxumab has the potential to transform the management of lung infections in ventilated patients,” said Mark Esser, vice president of R&D in microbial sciences and biopharmaceuticals at AstraZeneca. “We are delighted to enter into this licensing agreement with Aridis which we believe is well positioned to advance suvratoxumab. “

RELATED: Inhaled Antibody for COVID-19 Kills Coronavirus in Animals

The therapy, although under the wing of AstraZeneca, has achieved expedited designation in Phase 2 clinical trials in the United States were supported by The National Institute of Allergy and Infectious Diseases of the National Institutes of Health as part of their efforts to fight antibiotic resistance. The US research agency said that suvratoxumab is not an antibiotic but can be given with common treatments.


Source link

read more
Pneumonia prevention

Hospital Acquired Pneumonia Prevention Market Expected To Be Huge

Hospital Acquired Pneumonia Prevention Market

The research report on ‘Hospital Acquired Pneumonia Prevention Market 2020’ offers a holistic analysis of the business space, in tandem with a comprehensive overview of market segmentations. The report details the market scenario based on industry size and current position as well as volume and revenue with forecast till 2027. The study also emphasizes the crucial information regarding the geographic and competitive market landscape. The new report offers a powerful combination of the latest in-depth research studies on the Nosocomial Pneumonia Prevention market. The authors of the report are highly experienced analysts with in-depth knowledge of the market. Some of the major players in the global hospital pneumonia prevention market are Halyard Health, Sage Products, Intersurgical, Medline Industries.

Download Sample Pages of Nosocomial Pneumonia Prevention Market Report here: https://www.stratagemmarketinsights.com/sample/14210

[**NOTE: This report Sample includes;
o Brief Introduction to the research report
o Table of Contents (Scope covered as a part of the study)
o Top players in the market
o Research framework (presentation)
o Research methodology adopted by Stratagem Market Insights]

Competitive analysis:
The report covers the major players operating in the Nosocomial Pneumonia Prevention market along with the key strategies implemented to gain competitive advantage over majority of vendors, which provides a competitive outlook for the industry. The competitive landscape further includes details about the different players and their position at global and local level is also explained in detail in this compiled study. This information has been prepared by mapping business strategies and products with high revenue generation capabilities.

Manufacturer Detail:
Halyard health
Sage LLC Products
Intersurgical Ltd.
Medline Industries

Segmentation by product type
Oral care kit
Toothbrush
Swab
moisturizer
Mouthwash

Industry segmentation
Hospitals
Rehabilitation centers
Home care settings

The major strategic developments of the Hospital Pneumonia Prevention market including acquisitions and mergers, new product launches, agreements, partnerships, collaborations and joint ventures, research and development, and regional expansion of the major players involved in the Hospital Pneumonia Prevention market on a global and regional basis. The study provides a decisive view on the Nosocomial Pneumonia Prevention market by segmenting the market on the basis of product, end-user, and regions. All segments have been analyzed on the basis of present and future trends, and the Nosocomial Pneumonia Prevention market is estimated from 2020 to 2027. The regional segmentation includes the current and forecast demand for North America, Europe, l ‘Asia-Pacific, Latin America and the Middle East. East and Africa with its new bifurcation in the main countries.

Do not miss out on business opportunities in the Hospital Pneumonia Prevention market. Buy now and get crucial industry information that will help your business grow: https://www.stratagemmarketinsights.com/cart/14210

The Global Nosocomial Pneumonia Prevention Market report includes detailed TOC points:

1. Introduction
1.1 Study objectives
1.2 Market definition
1.3 Global Hospital Acquired Pneumonia Prevention Market Overview
2 Market segmentation
3 Market overview
3.1 Government initiatives on the rise
3.2 Strategic initiative by market players
4 executive summaries
5 premium information
6 Regulatory procedure
7 Global Hospital Acquired Pneumonia Prevention Market, By Type
8 Global Hospital Acquired Pneumonia Prevention Market, By Application
9 Global Hospital Acquired Pneumonia Prevention Market, By Deployment
10 Global Hospital Acquired Pneumonia Prevention Market, By End User
11 Global Hospital Acquired Pneumonia Prevention Market, By Distribution Channel
12 Global Hospital Acquired Pneumonia Prevention Market, Company Landscape
13 Company Profile
13.1 Company overview
13.2 Revenue analysis
13.3 Analysis by the company
13.4 Product portfolio

Customization of this report: This Nosocomial Pneumonia Prevention research report can be customized according to customer requirements. We’ll make sure you get the report that’s right for your needs.

New business strategies, challenges and policies are mentioned in the table of contents, inquire now (please use your work / company email id) @ https://www.stratagemmarketinsights.com/quiry/14210

Thanks a thousand times for reading! You can also request personalized information such as a study by chapter or by region according to your interests.

More related reports: Ajit_Blog

Contact us:
Mr. Shah
Overview of the Stratagems Market
Phone. : +1 415 871 0703
Email: [email protected]

About Us:
Stratagem Market Insights is a management consulting organization providing market intelligence and consulting services around the world. We bring the expertise of consultants with cumulative industry experience of over 70 years. The company has provided quantified B2B research and currently serves more than 350 clients worldwide. Our reports cover various end-use industries such as Aerospace & Defense, Agriculture, Food & Beverage, Automotive, Chemicals & Materials, Consumer Goods & Retail, electronics, energy, mining and utilities, pharmaceuticals, manufacturing and construction, healthcare and services and ICT.

This version was posted on openPR.


Source link

read more
Pneumonia prevention

Prevention of pneumonia: OHSU to test specialized breathing tubes

Pneumonia is the most common infection in sick patients in intensive care units. A new trial will test to see if a specialized tube can reduce the risk of pneumonia in emergency intubation situations. (Getty Images)

When taken to a hospital emergency room, few patients have the means to choose the type of breathing tube that will be inserted into their throat.

This is why OHSU is about to conduct a special type of clinical trial that recruits patients without their written consent. The United States Food and Drug Administration allows certain studies to be performed without written consent in emergency situations, provided that the patient has a high risk of dying without treatment, cannot speak because of their illness, no have no family available to speak on their behalf, and community members can opt out. (See the sidebar for unsubscribe instructions.)

The trial will compare two types of breathing tubes:

  • A standard tube currently in use in most emergency rooms and hospitals nationwide.

  • A specialized tube designed to reduce the risk of fluids leaking from the mouth and throat into the lungs, thereby reducing the risk of pneumonia.

The trial begins in April and is expected to last 36 months. It will enroll a total of 1,074 patients, half receiving the standard tube and the other half receiving the specialized tube. Known as a randomized controlled trial, the study will measure the benefits and risks resulting from specialized tubes compared to the standard tube.

The specialized tube has already been approved by the FDA as safe for clinical use. The new study will determine whether it is so effective that it should be adopted as the standard of care across the medical profession.

Myriam Treggiari (2014)

Miriam Treggiari, MD, Ph.D., MPH

“It could change clinical practice across the country and the world,” said Miriam Treggiari, MD, Ph.D., MPH, professor of anesthesiology and perioperative medicine at the OHSU School of Medicine who is leading the study.

The specialized tube includes a special balloon and an additional port that sucks fluids from the throat and mouth.

It is designed to reduce the risk of pneumonia, the most common infection in sick patients in intensive care units. Pneumonia can cause an increase in the time spent on a respirator and can increase the risk of death.

Participants will be followed for six months after placement of the breathing tube. While the tube is in place, researchers will watch for pneumonia and other possible complications. Six months after the breathing tube is removed, the study team will contact participants to determine if there are any lingering complications and their well-being.

The title of the study is “Randomized Trial of Endotracheal Tubes to Prevent Ventilator-Associated Pneumonia – Prevention Study 2” and is funded by the National Heart, Blood and Lung Institute of the National Institutes of Health with grants R61HL138650-01A1 and R33HL138650. Monitoring is provided by the FDA; the National Institute of the Heart, Blood and Lungs of the National Institutes of Health; and the OHSU Institutional Review Board and an independent Data Security Oversight Board.

Additional information:

If you wish to withdraw from the study, contact: 833-376-1027 or [email protected]

Details of the PreVent 2 study: apomocean.ohsu.edu


Source link

read more
Pneumonia prevention

Prevention of pneumonia is possible

Community-acquired pneumonia (CAP), an acute bacterial or viral alveolar infection of the lungs, manifests itself in a clinical spectrum.

CAP can be ambulatory pneumonia with anorexia, cough, dyspnea, and fever in otherwise healthy patients or so severe that it requires hospitalization (necrotizing or multilobar disease with septic shock). Pneumonia is the leading cause of death from infection in the United States and the eighth leading cause of death, along with influenza, and its incidence increases dramatically during influenza season (Figure1,3).1.2 In the United States, influenza and respiratory syncytial virus are common causes of viral pneumonia. Streptococcus pneumoniae is a common cause of bacterial pneumonia.3

RISK FACTORS

Anyone can get pneumonia from direct contact with respiratory secretions, but certain risk factors increase the likelihood (see Table 1.3). It should be noted that the influenza virus affects up to 20% of the general population each year. Pneumonia is one of the leading causes of death after influenza infection, particularly in the elderly and those with chronic illnesses or with co-morbidities. Influenza vaccination dramatically reduces influenza and pneumonia-related hospitalizations, with vaccine effectiveness ranging from 25 to 53%. In the elderly population, the efficacy of the vaccine is lower. For this reason, pharmacists should recommend one of the highly immunogenic influenza vaccines for the elderly.4.5

Many risk factors are well known, especially those associated with smoking and impaired lung function. Acute stroke is one that is underestimated. About 10% of people with acute stroke develop pneumonia.6 Pneumonia in this population is usually acquired in hospital and can be life threatening. Risk factors include chronic obstructive pulmonary disease (COPD), congestive heart failure, coronary artery disease, dysphagia, higher severity of strokes, male sex, advanced age, and pre-drug addiction. admission.6 Prophylaxis with antibiotics appears to reduce the incidence of post-stroke pneumonia, although study results are mixed.6.7 Pharmacists should also note an emerging factor: People who take or have recently used a benzodiazepine appear to be 1.25 times more likely to get pneumonia than those who do not. Although the reason for the association is unknown, the researchers suggest that relaxation of the esophageal sphincter and suppressing the immune system may increase the risk of pneumonia.8

A TRIAD OF PREVENTION TECHNIQUES

There are three approaches that can help prevent pneumonia, and pharmacy teams can help patients with all of them.

Stopping smoking is the most important action a patient can take to reduce the risk of CAP. Tobacco use impairs the immune system and lung function and often leads to COPD and increases the risk of pneumonia. Helping patients quit smoking is not easy, but with many different pharmacological interventions available, pharmacists can recommend suitable products effectively.9

Healthy living practices can also prevent infection. These include cleaning surfaces that people touch on a regular basis; cough or sneeze into a sleeve or tissue; manage ongoing medical conditions such as asthma, diabetes and heart disease; and wash your hands often and thoroughly. Also, removing mold from homes and workplaces and improving cleanliness and ventilation can help. Regular exercise also improves lung health.1.3

IMMUNIZATION

The third intervention, vaccination, is essential. Children under 2 years of age should be vaccinated against S pneumoniae and Haemophilus influenzae with a pneumococcal conjugate vaccine (PCV13) and against H influenzae type b. All healthy adults over 65 who have not received a dose should be vaccinated with PCV13 and then schedule pneumococcal polysaccharide vaccine at least 1 year later. The CDC also recommends the pneumococcal pneumonia vaccination for smokers and people aged 2 to 64 with chronic or immunocompromised conditions.ten This diet is especially important for patients with COPD. Pneumococcal vaccine has been shown to reduce the likelihood of CAP and COPD exacerbations. In addition, the annual flu shot reduces the likelihood of complications from the flu, including pneumonia.11.12

CONCLUSION

In 2016, the CDC reported 13.5 deaths per 100,000 Americans from influenza and pneumonia,13 the lowest rate ever recorded, against 53.7 per 100,000 before 1960 and 23.7 in 200013. But this number is still too high. Pharmacists can help reduce infections by recognizing pneumonia as a life-threatening disease, proactively fighting smoking, encouraging vaccination, and reminding patients that the flu and pneumonia are linked.

Jeannette Y. Wick, RPh, MBA, FASCP, is deputy director of the Office of Pharmacy Professional Development at the University of Connecticut School of Pharmacy at Storrs.

THE REFERENCES

  • Waterer GW, Rello J, Wunderink RG. Management of community-acquired pneumonia in adults. Am J Respir Crit Care Med. 2011; 183 (2): 157-164. doi: 10.1164 / rccm.201002-0272CI.
  • CDC, National Center for Health Statistics. Main causes of death. CDC website. cdc.gov/nchs/fastats/leading-causes-of-death.htm. Updated March 17, 2017. Accessed January 3, 2019.
  • Pneumonia can be prevented – vaccines can help. CDC website. cdc.gov/pneumonia/prevention.html. Updated October 18, 2018. Accessed January 3, 2019.
  • Heo JY, Song JY, Noh JY, et al. Effects of influenza vaccination on pneumonia in the elderly. Hum Vaccine Immunother. 2018; 14 (3): 744-749. doi: 10.1080 / 21645515.2017.1405200.
  • Ballinger MN, Standiford TJ. Post-influenza bacterial pneumonia: the host’s defenses have gone bad. J Interferon Cytokine Res. 2010; 30 (9): 643-652. doi: 10.1089 / jir.2010.0049.
  • Badve MS, Zhou Z, van de Beek D, Anderson CS, Hackett ML. Frequency of post-stroke pneumonia: systematic review and meta-analysis of observational studies. Int J AVC. 2019; 4 (2): 125-136. doi: 10.1177 / 1747493018806196.
  • Badve MS, Zhou Z, Anderson CS, Hackett ML. Efficacy and safety of antibiotics for preventing pneumonia and improving outcomes after acute stroke: systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2018; 27 (11): 3137-3147. doi: 10.1016 / j.jstrokecerebrovasdis.2018.07.001.
  • Sun GQ, Zhang L, Zhang LN, Wu Z, Hu DF. Benzodiazepines or related drugs and risk of pneumonia: systematic review and meta-analysis [published online January 8, 2019]. Int J Geriatr Psychiatry. doi: 10.1002 / gps.5048.
  • San-Juan-Rodriguez A, Newman TV, Hernandez I, et al. Impact of preventive services provided by community pharmacists on clinical, use and economic outcomes: a general review. Previous med. 2018; 115: 145-155. doi: 10.1016 / j.ypmed.2018.08.029.
  • Vaccination schedules. CDC website. cdc.gov/vaccines/schedules/index.html. Updated February 5, 2019. Accessed February 14, 2019.
  • Kislaya I, Rodrigues AP, Sousa-Uva M, et al. Indirect effect of 7-valent and 13-valent pneumococcal conjugate vaccines on hospitalizations for pneumococcal pneumonia in the elderly. PLoS A. 2019; 14 (1): e0209428. doi: 10.1371 / journal. pone.0209428.
  • Song JY, Noh JY, Lee JS, et al. Efficacy of polysaccharide influenza and pneumococcal vaccines against influenza-related outcomes including pneumonia and acute exacerbation of cardiopulmonary disease: analysis by dominant viral subtype and vaccine pairing. PLoS A. 2018; 13 (12): e0207918. doi: 10.1371 / journal. pone.0207918.
  • Flu and pneumonia deaths in the United States from 1950 to 2016 (per 100,000 population). Statista website. statista.com/statistics/184574/deaths-by-influenza-and-pneumonia-in-the-us-since-1950/. Accessed February 14, 2019.


Source link

read more